Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 401.25M | 730.80M | 442.93M | 399.36M | 611.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 401.25M | 730.80M | 442.93M | 399.36M | 611.09M |
| Cost of Revenue | 157.89M | 262.73M | 724.04M | 369.67M | 167.84M |
| Gross Profit | 243.36M | 468.08M | -281.11M | 29.69M | 443.26M |
| SG&A Expenses | 107.60M | 108.95M | 128.30M | 91.89M | 137.90M |
| Depreciation & Amortization | 717.00K | 691.00K | 677.00K | 677.00K | 667.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 348.96M | 372.37M | 853.02M | 462.24M | 495.51M |
| Operating Income | 52.29M | 358.43M | -410.08M | -62.88M | 115.58M |
| Income Before Tax | -1.75M | 343.17M | -278.30M | -194.05M | 153.64M |
| Income Tax Expenses | 3.14M | 12.22M | 4.55M | -14.10M | -43.25M |
| Earnings from Continuing Operations | -4.89M | 330.96M | -282.85M | -179.95M | 196.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.89M | 330.96M | -282.85M | -179.95M | 196.89M |
| EBIT | 52.29M | 358.43M | -410.08M | -62.88M | 115.58M |
| EBITDA | 62.70M | 369.03M | -404.83M | -44.43M | 126.42M |
| EPS Basic | -0.05 | 3.15 | -2.70 | -1.80 | 2.01 |
| Normalized Basic EPS | 0.22 | 2.05 | -2.52 | -0.40 | 0.73 |
| EPS Diluted | -0.05 | 2.88 | -2.70 | -1.80 | 1.89 |
| Normalized Diluted EPS | 0.22 | 1.76 | -2.52 | -0.40 | 0.67 |
| Average Basic Shares Outstanding | 105.43M | 104.99M | 104.79M | 100.24M | 98.01M |
| Average Diluted Shares Outstanding | 105.43M | 121.92M | 104.79M | 100.24M | 106.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |